KPC-Producing klebsiella pneumoniae strains that harbor AAC(6')-

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7597-7600

  Bremmer, Derek N ^a   Clancy, Cornelius J ^b,d   Press, Ellen G ^b   Almaghrabi, Reem ^b   Chen, Liang ^e   Doi, E Yohei ^b   Nguyen, M Hong ^b,c   Shieldsb, Ryan K ^b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE MODIFYING ENZYME AAC(6') IB; BACTERIAL ENZYME; CARBAPENEMASE; COLISTIN; COTRIMOXAZOLE; DORIPENEM; GENTAMICIN; LEVOFLOXACIN; RIFAMPICIN; TIGECYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG; ACYLTRANSFERASE; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BROTH DILUTION; CONTROLLED STUDY; DRUG POTENTIATION; GENE; GENE MUTATION; GENOTYPE; HUMAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OMPK36 GENE; PROMOTER REGION; SEQUENCE ANALYSIS; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION; GENETICS; GROWTH, DEVELOPMENT AND AGING; KLEBSIELLA INFECTION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ACETYLTRANSFERASES; AMIKACIN; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; GENE EXPRESSION; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION;

EID: 84912101206     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03831-14     Document Type: Article

References (20)

1. Clancy CJ, Hao B, Shields RK, Chen L, Perlin DS, Kreiswirth BN, Nguyen MH. 2014. Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing Klebsiella pneumoniae strains with various ompK36 genotypes. Antimicrob. Agents Chemother. 58:3521-3525. http://dx.doi.org/10.1128/AAC.01949-13.
2. Ramirez MS, Tolmasky ME. 2010. Aminoglycoside modifying enzymes. Drug Resist. Updat. 13:151-171. http://dx.doi.org/10.1016/j.drup.2010 .08.003.
3. Almaghrabi R, Clancy CJ, Doi Y, Hao B, Chen L, Shields RK, Press EG, Iovine NM, Townsend BM, Wagener MM, Kreiswirth B, Nguyen MH.Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. Antimicrob. Agents Chemother. 58: 4443-4451. http://dx.doi.org/10.1128/AAC.00099-14.
4. Jacoby GA, Blaser MJ, Santanam P, Hachler H, Kayser FH, Hare RS, Miller GH. 1990. Appearance of amikacin and tobramycin resistance due to 4 = -aminoglycoside nucleotidyltransferase [ANT(4=)-II] in gramnegative pathogens. Antimicrob. Agents Chemother. 34:2381-2386. http: //dx.doi.org/10.1128/AAC.34.12.2381.
5. Gaynes R, Groisman E, Nelson E, Casadaban M, Lerner SA. 1988. Isolation, characterization, and cloning of a plasmid-borne gene encoding a phosphotransferase that confers high-level amikacin resistance in enteric bacilli. Antimicrob. Agents Chemother. 32:1379-1384. http://dx.doi .org/10.1128/AAC.32.9.1379.
6. Li JJ, Sheng ZK, Deng M, Bi S, Hu FS, Miao HF, Ji ZK, Sheng JF, Li LJ.2012. Epidemic of Klebsiella pneumoniae ST11 clone coproducing KPC-2 and 16S rRNA methylase RmtB in a Chinese University Hospital. BMC Infect. Dis. 12:373. http://dx.doi.org/10.1186/1471-2334-12-373.
7. Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N. 2011. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother. 66: 48-53. http://dx.doi.org/10.1093 /jac/dkq408.
8. Lindemann PC, Risberg K, Wiker HG, Mylvaganam H. 2012. Aminoglycoside resistance in clinical Escherichia coli and Klebsiella pneumoniae isolates from Western Norway. APMIS 120:495-502. http://dx .doi.org/10.1111/j.1600-0463.2011.02856.x.
9. Kim SY, Park YJ, Yu JK, Kim YS. 2011. Aminoglycoside susceptibility profiles of Enterobacter cloacae isolates harboring the aac(6=)-Ib gene. Korean J. Lab Med. 31:279-281. http://dx.doi.org/10.3343/kjlm.2011.31 .4.279.
10. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing (M100-S21). Clinical and Laboratory Standards Institute, Wayne, PA.
11. European Society of Clinical Microbiology and Infectious Diseases. 2013. Clinical breakpoints. European Committee on Antimicrobial Susceptibility Testing, London, United Kingdom. http://www.eucast.org/.
12. Galvez R, Luengo C, Cornejo R, Kosche J, Romero C, Tobar E, Illanes V, Llanos O, Castro J. 2011. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity. Int. J. Antimicrob. Agents 38:146-151. http://dx.doi.org/10.1016/j.ijantimicag .2011.03.022.
13. Mahmoudi L, Mohammadpour AH, Ahmadi A, Niknam R, Mojtahedzadeh M. 2013. Influence of sepsis on higher daily dose of amikacin pharmacokinetics in critically ill patients. Eur. Rev. Med. Pharmacol. Sci. 17:285-291.
14. de Montmollin E, Bouadma L, Gault N, Mourvillier B, Mariotte E, Chemam S, Massias L, Papy E, Tubach F, Wolff M, Sonneville R. 2014. Predictors of insufficient amikacin peak concentration in critically ill patients receiving a 25 mg/kg total body weight regimen. Intensive Care Med. 40:998-1005. http://dx.doi.org/10.1007/s00134-014-3276-x.
15. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. 1999. Aminoglycosides: activity and resistance. Antimicrob. Agents Chemother. 43:727-737.
16. Yu F, Wang L, Pan J, Yao D, Chen C, Zhu T, Lou Q, Hu J, Wu Y, Zhang X, Chen Z, Qu D. 2009. Prevalence of 16S rRNA methylase genes in Klebsiella pneumoniae isolates from a Chinese teaching hospital: coexistence of rmtB and armA genes in the same isolate. Diagn. Microbiol. Infect. Dis. 64:57-63. http://dx.doi.org/10.1016/j.diagmicrobio.2009.01 .020.
17. Clancy CJ, Chen L, Hong JH, Cheng S, Hao B, Shields RK, Farrell AN, Doi Y, Zhao Y, Perlin DS, Kreiswirth BN, Nguyen MH. 2013. Mutations of the ompK36 porin gene and promoter impact responses of ST258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob. Agents Chemother. 57:5258-5265. http: //dx.doi.org/10.1128/AAC.01069-13.
18. Hirsch EB, Guo B, Chang KT, Cao H, Ledesma KR, Singh M, Tam VH. 2013. Assessment of antimicrobial combinations for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. J. Infect. Dis. 207: 786-793. http://dx.doi.org/10.1093/infdis/jis766.
19. Elemam A, Rahimian J, Doymaz M. 2010. In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J. Clin. Microbiol. 48:3558-3562. http://dx.doi.org/10 .1128/JCM.01106-10.
20. Tascini C, Tagliaferri E, Giani T, Leonildi A, Flammini S, Casini B, Lewis R, Ferranti S, Rossolini GM, Menichetti F. 2013. Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 57:3990-3993. http://dx.doi.org/10.1128/AAC.00179-13.